Form 4: IGM Biosciences CSO Exercises Stock Options and Acquires Shares

Bruce Keyt, Chief Scientific Officer of IGM Biosciences, exercised stock options to acquire 3,026 shares of common stock at $0.93 per share on March 1, 2024.

Summary

• On March 1, 2024, Bruce Keyt, the Chief Scientific Officer of IGM Biosciences, exercised stock options.
• This transaction resulted in the acquisition of 3,026 shares of IGM Biosciences common stock at a price of $0.93 per share.
• Following the transaction, Keyt directly owns 129,551 shares and indirectly owns 4,039 shares through his spouse.
• The stock options were vested and exercisable as of March 1, 2024.
• The transaction was reported on March 5, 2024.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a routine disclosure of insider trading activity. The exercise of options could be seen as a slightly positive signal, but it's not a major event.

Positives

• The exercise of stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, which is required when company insiders (officers, directors, or those holding more than 10% of the company's shares) buy or sell the company's securities. It provides transparency into insider transactions.

Stakeholder Impact

• The transaction could have a minor impact on shareholders, as it increases the number of shares outstanding.

Key Dates